| Date | Title | Description |
| 20.08.2026 | Bacteria, Billions and Buzzwords: Is the Gut Microbiome Startup Boom Backed by Science? | Investors have bankrolled hundreds of millions of pounds into companies that claim they can decode the inner workings of your gut. Behind the personalised nutrition apps and at-home stool tests, as well as the pitch deck for the next genera... |
| 23.06.2025 | Enterome: $19 Million Secured To Fund Development Of OncoMimics Immunotherapy To Treat Follicular Lymphoma | Enterome, a clinical-stage company developing first-in-class OncoMimics immunotherapies to treat cancer, announced that it has raised $19 million in new private financing to advance its lead clinical program, EO2463 OncoMimics immunotherapy... |
| 12.06.2025 | Enterome Raises $19M in Funding | Enterome, a Paris, France-based clinical-stage company developing OncoMimics immunotherapies to treat cancer, raised $19M in funding.
The round consisted of:
$9M from new investor The Institute for Follicular Lymphoma Innovation (IFLI)
$10M... |
| 11.12.2024 | Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024 | Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite stable metastatic colorectal cancer (mCRC)... |
| 06.11.2024 | Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting | Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting initial data from Cohort 2 as monotherapy in a “watch-and-wait” setting, and findings on a predic... |
| 24.05.2024 | Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024 | - Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients treated with EO2463 upon addition of lenalidomide ± rituximab
- EO2463 rapidly expands memory CD8+ T cells spe... |
| 25.04.2024 | Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | Poster presentation to highlight updated data from ongoing Phase 1/2 of EO2463 monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL)
PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a cl... |
| 17.04.2024 | Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma | EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against tumor-associated driver antigens due to their strong cross-reactivity with... |
| 06.03.2024 | Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024 | - |
| 13.11.2023 | Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023 | Oral Presentation at SNO will feature updated results from the Phase 1/2 EOGBM1-18/ROSALIE study
PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liqu... |
| 31.05.2023 | Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO | /EIN News/ -- Updated clinical data highlight promising efficacy and sustained CD8+ T cell expansion
Early data from final cohort could provide validation of the EO2401 + nivolumab + bevacizumab combination outcome
Paves the way to next pot... |
| 12.12.2022 | Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma | EO2401 is a first-in-class OncoMimics™ peptide-based immunotherapy able to rapidly activate and significantly expand existing effector memory CD8+ T cells against tumor-associated driver antigens due to their strong cross-reactivity with On... |
| 07.12.2022 | Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022 | Enterome will also be presenting another poster on the therapeutic development of OncoMimics™ peptides
PARIS, Dec. 7, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs... |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021.
This event will con... |
| 24.08.2020 | These 10 ambitious French tech startups obtained highest VC funding in Q2 2020 | Undoubtedly, the COVID-19 pandemic outbreak has impacted several businesses across the world causing an economic downturn. And, many early-stage businesses and startups have faced the worst dent in their operations forcing them to layoff em... |
| 26.06.2020 | Biopharma business Enterome scores €46.3M Series E | Enterome has received a €46.3 million investment. New backers SymBiosis and Takeda Pharmaceutical joined the round, alongside existing investors. The French business develops therapies for cancer, autoimmune, inflammatory and metabolic dise... |
| 25.06.2020 | Enterome Completes $52.6M Financing | ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today announces a new financing totaling €46.3 million ($52.6million)... |
| 25.06.2020 | Enterome Closes €46.3M Financing Round | Enterome SA, a Paris, France-based clinical-stage biopharmaceutical company leveraging its knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, raised €46.3m ($52.6m) in funding.
As part of this finan... |
| 04.01.2018 | Enterome Raises €32M in Series D Financing; Secures €40M Loan Facility from EIB | Enterome SA, a Paris, France and Cambridge, MA-based clinical-stage biotech company, raised €32m in Series D financing.
All current investors – Seventure, Health for Life Capital, LundbeckFonden Ventures, Omnes Capital and Nestlé Health Sci... |
| 04.01.2018 | Enterome Lands Series D Funding | ENTEROME SA, a clinical-stage biotech company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, announces that it has raised €32 m... |
| 11.12.2016 | Enterome Appoints Jai Patel as CMO | Enterome SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce the appointments of Jai Patel, Ph.D. as Chief Medical Officer (CMO), and Roger J. Garceau, MD as Non-executive ... |
| 20.04.2016 | Enterome Bioscience Raises €14.5M in Series C Funding | Enterome Bioscience SA, a Paris, France and Cambridge, USA-based developer of pharmaceuticals and diagnostics based on the gut microbiome, raised €14.5m in Series C funding.
The round was led by existing investors Seventure (including from ... |
| 01.05.2014 | Enterome Bioscience Raises €10M in Series B Funding | Enterome Bioscience SA, a Paris, France-based developer of innovative disease management solutions based on understanding of the gut microbiome, raised €10m in the first tranche of a Series B funding.
The round was led by existing investors... |
| 23.03.2012 | Enterome Raises €5M in Series A Funding | Enterome, a Paris, France-based a stratified medicine company developing biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine (metabolic and bowel diseases), has... |
| - | ENTEROME | “We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.” |
